FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				APPLICATION NO.: 10/017,905		ATTY. DOCKET NO.: B0801.70238US00		
				FILING DATE: December 14, 2001		CONFIRMATION NO.: 7653		
STATEMENT BY APPLICANT				APPLICANT: Paul Ridker et al.				
Sheet	Sheet 1 of 1		GROUP ART UNIT: 1644		EXAMINER: G.R. Ewoldt			
<u> </u>				ILS. I	PATENT DOCUMENTS	L		
Examiner's Initials #	Cite No.	U.S. Patent Documer				Date of Publication or Issu		on or Issue
		Number		Kind Code	Name of Patentee or Applicant of Cited Document		of Cited Document MM-DD-YYYY	
				FOREIG	N PATENT DOCUMENTS			
Examiner's Initials #	Cite	Foreign Patent Docume		nent	Name of Patentee or Applican	t of Cited	Date of Publication of	Translation (Y/N)
	No.	Office/ Country	Number	Kind Code	Document C		Cited Document MM-DD-YYYY	
					PATENT LITERATURE DOCU			
Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine journal serial symposium catalog etc.) date page(s) volume-issue number(s) publisher Translation						Translation (Y/N)
		ASAKIDA Toshio "Clycosylated Hemoglobin (HhAle) and Diabetes Mellitus" Seitai no Kagaku						Y
		KUMON, Y. et al. "Serum Amyloid A Protein in Patients with Non-Insulin-Dependent Diabetes						
		Mellitus", Clin. Biochem., 1994, December, Vol. 27, No. 6, p. 469-473.						
		NAKAHARA, Rieko et al. "The Significance of Blood Leptin Concentration Measurements in Type 2 Diabetes patients", Proceedings of the 47 th National Congress of the Japanese Society of						Y
		Laboratory Medicine, September 25, 2000, Vol. 48, Supplement, p. 241. Abstract only.						
		PICKUP et al., "Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production						
		in type 2 diabetes," <i>Life Sciences</i> , June 2000, Vol. 67, pgs. 291-300.						
		UCHIMURA, I. et al. "Interleukin-6 and its Hemorhelogical Effects in Diabetes Mellitus", Biorheology, 1992, Vol. 29, No. 1, p. 27.						
	1	VIJAN, N. et al., "Screening, Prevention, Counseling, and Treatment for the Complications of Type II						
		Diabetes Mellitus. Putting Evidence into Practice" J Gen Intern Med, 1997, Vol. 12, pgs. 567-580.						

EXAMINER	DATE CONSIDERED

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 12870G163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).